StreetAlpha.app
Home › Stocks › NKTX

Nkarta, Inc. (NKTX)

Healthcare
$1.14
▲ +1.34%
LAST CLOSE · NOV 20

Nkarta develops engineered natural killer cell therapies for autoimmune diseases, led by its candidate NKX019. It last closed at $1.14 on Nov 20, up 1.34% on the day. The next earnings report for NKTX is expected around Wed, Mar 24, 2027, after the close. Over its last 8 reports the stock moved an average of 11.2% the session after earnings. Over the last 12 months NKTX insiders bought $0 of stock on the open market and sold $70K, according to SEC Form 4 filings.

AI Auto Pilots
Is NKTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NKTX.

Key Stats

Fiscal 2025
Results
Revenue
$0
Net income
−$104.1M
EPS (diluted)
−$1.41
Free cash flow
−$89.9M
Valuation
Market cap
$81.4M
71.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$48.4M
At Sep 30
Shareholder equity
$215.7M
Shares outstanding
71.7M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $0$0FY2025

From NKTX's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 5).

Next report
Mar 24
Estimated date · After the close
Reported EPS
—
Not on file yet
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
How NKTX moved after its last 8 reports
Average move the session after a report ±11.2%
Nov 5, 2026After the close+10.2%
Aug 10, 2026After the close−5.3%
May 12, 2026After the close−6.7%
Mar 25, 2026After the close+0.5%
Nov 10, 2025After the close+2.5%
Aug 12, 2025After the close+12.8%
May 14, 2025After the close−8.0%
Mar 26, 2025After the close+43.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NKTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NKTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NKTX

Technical Analysis

NKTX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 29% below its 20 day and 78% below its 50 day average. It is 118% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the swing low (Nov 9) at $1.13, and the nearest resistance the Pivot at $1.15.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 14.8%/day
Key levels
$3.7252 week high+226.3%
$2.47200 day average+116.7%
$2.32100 day average+103.5%
$2.0250 day average+77.2%
$1.84Swing high (Nov 6)+61.4%
$1.4620 day average+28.1%
$1.20Pivot R1+5.3%
$1.15Pivot+0.9%
$1.14Last close
$1.13Swing low (Nov 9)−0.9%
$1.1052 week low−3.5%
$1.09Pivot S1−4.4%
Indicators
RSI (14)30.63Weak, oversold below 30Neutral
MACD-0.24Below its signal lineBearish
Stochastic4.1Near the bottom of its rangeOversold
ADX (14)48.5Strong downtrend
Williams %R-95.9Oversold below −80, overbought above −20Oversold
CCI (20)-108.5Oversold below −100, overbought above 100Oversold
Rate of change−34.4%Change over 10 sessionsBearish
ATR (14)$0.17Typical daily range, 14.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NKTX

What happened before

See how NKTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NKTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NKTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NKTXHow many large options trades hit NKTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NKTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●58 buying vs 64 selling
  • ●Held by funds -0.1 pts
  • ▼Funds holding -12
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding124136−8.8%
In funds' top 10110.0%
Held by funds82.7%82.8%−0.1 pts
New / increased7 / 5126 / 52−25.6%
Reduced / sold out44 / 2036 / 14+28.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NKTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NKTX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$70K3 sales · 2 insiders
2026-01 sold $66K2026-06 sold $5KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 18Paul J HastingsCEOSale1,776$2.71$5K
Jan 15Nadir MahmoodPresidentSale5,649$2.07$12K
Jan 15Paul J HastingsCEOSale26,046$2.07$54K
Jun 18, 2025Paul J HastingsCEOSale1,790$1.79$3K
Jan 15, 2025Alicia J. HagerChief Legal OfficerSale9,584$2.20$21K
Jan 15, 2025Paul J HastingsCEOSale17,378$2.20$38K
Every insider buy and sale for NKTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NKTX insider trades →

From SEC Form 4 filings by NKTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NKTX is in one of them and how their past NKTX trades turned out.

NKTX in the AI portfolios
Loading…

NKTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NKTX in an article yet. Here's the latest on the wider market.

NKTX in the news

About Nkarta

Nkarta is a clinical stage biopharmaceutical company based in South San Francisco, California. It develops engineered natural killer cell therapies made from cells donated by healthy people and produced in advance, so they can be given to patients without waiting for a custom batch. Its lead product candidate, NKX019, targets CD19 and is being studied in autoimmune diseases such as lupus nephritis and systemic sclerosis. The company aims its therapies at people living with these conditions.

Headquarters
South San Francisco, CA